2015 Press Releases | Newsroom | Medtronic

2015 Press Releases


201520142013201220112010
Search News Releases
 
DateTitle  
08/25/15Medtronic to Acquire Twelve, Inc., Developer of Transcatheter Mitral Valve Replacement Device
DUBLIN - August 25, 2015 - In support of the company's therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. ("Twelve"), a privately-held medical device company based in Redwood City, Calif., focused on the development of a transcatheter mitral valve replacement (TMVR) device. Twelve is the twelfth company spun out from the premier medical device incubator The Foundry. "Upon close, this acquisitio... 
Download PDFPrinter Friendly Version
08/21/15Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2016
DUBLIN - August 21, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2016 second quarter cash dividend of $0.38 per ordinary share, representing a 25 percent increase over the prior year.  This quarterly declaration is consistent with the dividend announcement made by the company in June.  Medtronic has increased its annual dividend payment for the past 38 consecutive years, and is a constituent of the S&P 500 Dividend Aristocrats index.  The dividend is p... 
Download PDFPrinter Friendly Version
08/20/15Medtronic Announces 2015 Global Heroes Team, Marking 10 Years of the Program and 234 Runners Honored
Distance Runners from Six Continents Benefitting from Medical Technology to Run Medtronic Twin Cities Marathon Events this October MINNEAPOLIS - August 20, 2015 - Twenty-five long-distance runners who benefit from medical technology will be honored as the 2015 "Medtronic Global Heroes" when they run as a team in the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile on Sunday, October 4, 2015. This year's team includes runners from six continents and 16 different countries: Bra... 
Download PDFPrinter Friendly Version
08/20/15Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2016
DUBLIN - August 20, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2016 on Thursday, September 3, 2015. A news release will be issued at approximately 6:15 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for the first fiscal quarter, which ended July 31, 2015. Medtronic will host a webcast at 7:00 a.m. Central Dayligh... 
Download PDFPrinter Friendly Version
08/14/15Medtronic Supports Boston Area Retreat & Refresh Stroke Camp for Stroke Survivors and Caregivers
Brigham and Women's Hospital, Massachusetts General Hospital and Spaulding Rehabilitation Hospital Bring Stroke Camp to Area Stroke Survivors and Caregivers DUBLIN - August 14, 2015 - Three leading Boston-area hospitals - Brigham and Women's Hospital, Massachusetts General Hospital and Spaulding Rehabilitation Hospital - have teamed up to bring stroke victims the Retreat & Refresh Stroke Camp (Stroke Camp), sponsored by Medtronic. Stroke Camp, a three-day retreat for stroke survivors, caregive... 
Download PDFPrinter Friendly Version
08/05/15Medtronic Launches the Entrust(TM) Delivery System in the United States
New System Provides an Easy to Use, Accurate and Controlled, One-Handed Stent Delivery System When Treating Patients with Peripheral Arterial Disease DUBLIN - August 5, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of its Entrust(TM) delivery system in the United States. The new Entrust delivery system enables physicians to place Medtronic's EverFlex(TM) self-expanding peripheral stent, while maintaining a low profile and providing the ease of a one-handed device. "The Entru... 
Download PDFPrinter Friendly Version
08/04/15Medtronic, Inc. Commences Registered Exchange Offer for Certain of its Senior Notes
DUBLIN - August 4, 2015 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of exchange offers (the "exchange offers") with respect to: (i) up to $500,000,000 aggregate principal amount of outstanding Floating Rate Senior Notes due March 15, 2020 issued by Medtronic, Inc. ("Medtronic, Inc."), together with the subsequent full and unconditional guarantees of such notes by the Company and Medtronic Global Holdings S.C.A. ("Medtronic Luxco... 
 Printer Friendly Version
08/03/15CMS Grants New Technology Add-On Payment for Inpatient Use of Medtronic's Drug-Coated Balloon
Decision Will Provide Patients with Additional Access to New Medical Device with Potential to Improve Standard of Care for Peripheral Arterial Disease in Vessels Above the Knee DUBLIN -- August 3, 2015 -- Medtronic plc (NYSE: MDT) announced today that the U.S. Centers for Medicare and Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for the company's IN.PACT® Admiral® drug-coated balloon (DCB) under the Medicare hospital inpatient prospective payment system (IPPS). The... 
Download PDFPrinter Friendly Version
07/30/15Medtronic Supports First Retreat & Refresh Stroke Camp for Stroke Survivors and Caregivers Held in Minnesota
Stroke Survivors and Caregivers Relax, Unwind and Recharge in Supportive Environment with the Help of Abbott Northwestern Hospital DUBLIN - July 30, 2015 - Medtronic will sponsor Minnesota's first Retreat & Refresh Stroke Camp (Stroke Camp), a three-day retreat for stroke survivors, caregivers and family members being held Aug. 7-9, 2015 in Ironwood Springs, Minnesota, in association with Abbott Northwestern Hospital, part of Allina Health. This is the second of four rehabilitative camps sponso... 
Download PDFPrinter Friendly Version
07/15/15Tissue is the Issue When Performing a Biopsy for Potential Lung Cancer
-Company Launches GenCut(TM) Core Biopsy System for Minimally Invasive Use with the superDimension(TM) Navigation System for Lung Tissue Biopsies- -Multiple Lung Core Tissue Samples Now Possible with a Single Pass- DUBLIN - July 15, 2015 - Medtronic (NYSE:MDT) now offers the GenCut(TM) core biopsy system, a unique lung tissue biopsy tool for use with the superDimension(TM) navigation system. The superDimension(TM) system enables a minimally invasive approach to accessing difficult-to-reach are... 
Download PDFPrinter Friendly Version
07/13/15Medtronic to Acquire RF Surgical Systems, Developer of Detection System for the Prevention of Retained Surgical Sponges
Technology Designed to Prevent Surgical-Related "Never Events" DUBLIN-- July 13, 2015 -- Medtronic plc (NYSE:MDT) today announced it has signed  a definitive agreement to acquire RF Surgical Systems, Inc., a medical device company based in Carlsbad, Calif., focused on the detection and prevention of retained surgical items (sponge, gauze or towel) for approximately $235 million. Additional terms of the acquisition were not disclosed. Despite rigorous surgical sponge counting protocol... 
Download PDFPrinter Friendly Version
07/08/15Medtronic Awards $1.1 Million in Twin Cities Health Access Grants
Medtronic Philanthropy Grants Support 22 Local Organizations Committed to Expanding Access to Healthcare for the Underserved Minneapolis - July 8, 2015 - Medtronic Philanthropy has recently awarded $1.1 million in Health Access Grants to 22 Minnesota-based nonprofit organizations, supporting each to expand healthcare services in underserved communities across the metropolitan area, with an emphasis on such chronic conditions as heart disease and diabetes.  Each organization listed below will rec... 
Download PDFPrinter Friendly Version
07/08/15Medtronic Announces the Global Launch of the CD Horizon® Solera® Voyager (TM) Spinal System
DUBLIN - July 8, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of the CD HORIZON® SOLERA® VOYAGER(TM) Spinal System for Minimally Invasive Spine procedures. Available today in countries around the world, the CD HORIZON® SOLERA® VOYAGER(TM) System expands upon the transforaminal lumbar interbody fusion (TLIF) procedure by offering multiple, minimally invasive rod insertion options and enabling a seamless 3D-navigated surgical experience.  The announcement was made during the 22nd an... 
Download PDFPrinter Friendly Version
07/02/15Data Demonstrates Durability of Medtronic's VenaSeal Closure System, a Non-Tumescent, Non-Thermal and Non-Sclerosant Procedure for Chronic Venous Insufficiency
12 month closure rates for the VenaSeal closure system comparable to radiofrequency ablation   DUBLIN -- July 2, 2015 -- Medtronic plc (NYSE: MDT) today announced the twelve-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal(TM) closure system for the treatment of incompetent greater saphenous veins with a 96.8 percent closure rate.  The results were presented by National Principal Investigator, Nick Morrison, M.D., Morrison Vein Institute... 
Download PDFPrinter Friendly Version
06/30/15Medtronic Announces Date for 2015 Annual Meeting
Annual Meeting to be held in Dublin, Ireland on December 11, 2015  DUBLIN - June 30, 2015 - The board of directors of Medtronic plc (NYSE: MDT) announced that the company's annual meeting of shareholders will be held at 9:00 a.m. Irish Standard Time, on Friday, December 11, 2015 at the Conrad Hotel, Earlsfort Terrace, Dublin, Ireland.  Shareholders of record at the close of business on October 12, 2015, will be eligible to vote at the meeting. The 2015 Annual Meeting will be the first to be held... 
Download PDFPrinter Friendly Version
06/29/15American Heart Association's New Stroke Treatment Guidelines Establish Stent Retrievers as First-Line Endovascular Treatment for Acute Ischemic Stroke
DUBLIN - June 29, 2015 - Today, the American Heart Association/American Stroke Association (AHA/ASA) published new stroke treatment guidelines that recommend the use of stent retriever technology - such as Medtronic plc's (NYSE: MDT) SolitaireTM stent retriever device - in conjunction with the current standard of care, IV-tPA, as a first-line treatment for eligible patients. The guidelines are based on a panel of experts' analysis of the results from five global clinical trials published in The ... 
Download PDFPrinter Friendly Version
06/25/15Medtronic Announces Expansion of MR-Conditional Products with U.S. Launch of Advisa SR MRI(TM) SureScan® Pacing System
Single-Chamber Pacemaker Allows for Full-Body MRI Scans Without Positioning Restrictions DUBLIN- June 25, 2015 - Medtronic plc (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of the Advisa SR MRI(TM) SureScan® single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging (MRI) scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan le... 
Download PDFPrinter Friendly Version
06/25/15Medtronic Names Geoff Martha Executive Vice President and President, Restorative Therapies Group
Martha Succeeds Christopher J. O'Connell; Bill Burke Named Medtronic Chief Integration Officer DUBLIN - June 25, 2015 - Medtronic plc (NYSE: MDT) announced today that it has named Geoff Martha as executive vice president and president, Medtronic Restorative Therapies Group (RTG), effective immediately.   Martha will replace Christopher J. O'Connell, who was selected to become chief executive officer of a public company. "Chris has passionately served Medtronic for the past 21 years ... 
Download PDFPrinter Friendly Version
06/24/15World's Smallest Pacemaker, Medtronic Micra TPS, Wins Top European Innovation Award for 2015
Award Follows Late-breaking Presentation Showing Medtronic Micra Transcatheter Pacemaker Meets Initial Safety and Performance Measures DUBLIN and MILAN - June 24, 2015 - Medtronic plc (NYSE: MDT) today announced that its Micra® Transcatheter Pacing System (TPS) has won the top innovation award for practice improvement at EHRA EUROPACE-CARDIOSTIM 2015 in Milan. The award is selected by an international panel of experts, scientists and physicians who review the competing products and choose the ... 
Download PDFPrinter Friendly Version
06/23/15Medtronic Implements Worldwide Voluntary Recall for Certain Lots of Neonatal and Pediatric Tracheostomy Tubes
DUBLIN - June 23, 2015 - Medtronic (NYSE: MDT) announced that on May 8, 2015, it began notifying hospitals and distributors worldwide that affected lots of its Covidien Shiley(TM) tracheostomy tubes were formed with a wider-angle bend than standard models manufactured after November 29, 2012. The company initiated the field action following a small number of customer complaints that included reports of 12 serious patient injuries, such as breathing difficulties that impacted oxygen levels immed... 
Download PDFPrinter Friendly Version
06/23/15Medtronic Announces FDA Approval for New TAVR System, Introduces First and Only Recapturable Heart Valve in U.S.
CoreValve® Evolut(TM) R Recapturable and Repositionable Heart Valve Improves Positioning Accuracy and Control During Deployment DUBLIN - June 23, 2015 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the new recapturable, self-expanding CoreValve® Evolut(TM) R System. The first-and-only recapturable and repositionable device available in the U.S., the Evolut R System is approved for transcatheter aortic valve replacement (TAVR) ... 
Download PDFPrinter Friendly Version
06/22/15Medtronic Calls for Applications for 2015 Bakken Invitation Award
Ten Honorees Will Each Earn a $20,000 Grant DUBLIN - June 22, 2015 - Medtronic plc (NYSE: MDT) announced today that it is seeking applications for the 2015 Bakken Invitation Award, a global program honoring and connecting people who have overcome health challenges with the help of medical technology and are now selflessly giving back to their communities. Currently in its third year, the Bakken Invitation Award will honor ten inspirational people who use their "extra life" - gained ... 
Download PDFPrinter Friendly Version
06/22/15World's Smallest Pacemaker, Medtronic Micra TPS, Featured in Late-Breaking Trial Session at EUROPACE 2015
Global clinical trial finds Medtronic Micra Transcatheter Pacemaker Meets Initial Safety and Performance Measures DUBLIN and MILAN - June 22, 2015 - Medtronic plc (NYSE: MDT) today reported study results of its Micra® Transcatheter Pacing System (TPS) at a late-breaking clinical trials session at EHRA EUROPACE-CARDIOSTIM 2015 in Milan. The study results demonstrated that the miniaturized pacemaker met initial safety and performance measures in its global clinical trial. Of the first 140 patie... 
Download PDFPrinter Friendly Version
06/20/15Endurant AAA Stent Graft Maintains Durable, Consistent and Proven Outcomes for Abdominal Aortic Aneurysm Repair in Long-Term Follow-Up
Five-Year Results from U.S. IDE Study Presented at Society for Vascular Surgery Meeting CHICAGO - June 20, 2015 - Selected for nearly one of every two endovascular abdominal aortic aneurysm (AAA) repairs globally, the Endurant AAA stent graft system from Medtronic plc (NYSE: MDT) maintained durable, consistent and proven outcomes through five years of follow-up in the company's U.S. clinical study of the implantable medical device, according to new clinical data presented today at the Society f... 
Download PDFPrinter Friendly Version
06/19/15Medtronic Acquires Aptus Endosystems
Aptus Endosystems' Helical Anchor Technology Complements Medtronic's Aortic Stent Platform for the Treatment of Complex Aortic Disease DUBLIN-- June 19, 2015 -- Medtronic plc (NYSE:MDT) today announced it has acquired  the assets of Aptus Endosystems, Inc., a Sunnyvale, Calif. based, privately held medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR). Medtronic completed its acquisition of the... 
Download PDFPrinter Friendly Version
06/19/15Medtronic Announces Acquisition of CardioInsight Technologies, Developer of Non-Invasive Cardiac Mapping System
DUBLIN - June 19, 2015 - Medtronic plc (NYSE: MDT) today announced that it has acquired CardioInsight Technologies, Inc. ("CardioInsight"), a privately-held, Cleveland-based medical device company that has developed a new approach to improve the mapping of electrical disorders of the heart. CardioInsight will become part of the Medtronic Atrial Fibrillation Solutions business in the Cardiac Rhythm and Heart Failure division. Medtronic completed its acquisition of CardioInsight on a deb... 
Download PDFPrinter Friendly Version
06/19/15Medtronic Increases Cash Dividend by 25 Percent
Dividend Payout Ratio Now Approximately 35%; Targeting 40% Dividend Payout Ratio Within Next Few Years DUBLIN - June 19, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a 25 percent increase in its cash dividend for fiscal year 2016, raising the quarterly amount to $0.38 per ordinary share for an annual amount of $1.52 per ordinary share.  Today's announcement marks the 38th consecutive year of an increase in the dividend payment for Medtronic, a constituent of the S&P ... 
Download PDFPrinter Friendly Version
06/17/15Medtronic announces financial investment in Arsenal AAA, LLC
DUBLIN -- June 17, 2015 -- Medtronic plc (NYSE:MDT) today announced a financial investment in Arsenal AAA, LLC ("Arsenal AAA"), a wholly owned subsidiary of Arsenal Medical, Inc. ("Arsenal Medical"). In return, Medtronic received an option to acquire Arsenal AAA after the company achieves certain milestones. Financial terms of the investment were not disclosed. Arsenal AAA is developing a proprietary foam and delivery mechanism designed to fill the aneurysmal sac around an en... 
 Printer Friendly Version
06/10/15Medtronic Initiates U.S. Launch of Fortrex(TM) PTA Balloon
The Fortrex PTA Balloon Provides High Pressure Solution to Maintain Arteriovenous Access DUBLIN -- June 10, 2015 -- Medtronic plc (NYSE: MDT) announced today the launch of the Fortrex(TM) over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex PTA balloon catheter utilizes a high pressure balloon to break up the blockages and open the vessels to help maintain arteriovenous (AV) access in the peripheral vascular system. "Being able to maintain AV acce... 
Download PDFPrinter Friendly Version
06/09/15New Bariatric Surgery Device from Medtronic Makes the Most Common Weight Loss Procedure in U.S. More Consistent and Efficient
GastriSail(TM) Gastric Positioning System Combines Benefits of Three Devices Into One DUBLIN - June 9, 2015 - Furthering its commitment to fight obesity with innovative bariatric surgical solutions, Medtronic (NYSE:MDT) now offers the GastriSail(TM) gastric positioning system to help promote more consistent sleeve creation1 and greater procedural efficiency1 within the sleeve gastrectomy procedure, the most commonly performed weight loss procedure in the U.S.2 Developed by Medtronic's Minimal... 
Download PDFPrinter Friendly Version
06/08/15BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart(TM) Technology Designed to Improve Insulin Pump Therapy
New Innovation Demonstrates Reductions in Flow Interruptions, Including Silent Occlusions BOSTON, MA - JUNE 8, 2015 - BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic (NYSE: MDT) today announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart(TM) technology. An insulin infusion set delivers insulin from the pump to the body and is a critical part of the overall pump system. As part of ... 
Download PDFPrinter Friendly Version
06/06/15Medtronic Accelerates Path to Artificial Pancreas with New MiniMed 640G Data and Start of Hybrid Closed Loop Trial
MiniMed 640G System Shown to Further Reduce Hypoglycemia; Pivotal Study to Examine Safety of Hybrid Closed Loop System for People with Diabetes BOSTON - June 6, 2015 - As part of its commitment to developing an artificial pancreas for people with diabetes, Medtronic plc (NYSE:MDT) today announced results from the European User Evaluation of the MiniMed® 640G system, which demonstrated that the pump's exclusive SmartGuard technology can reduce hypoglycemia (low blood glucose) and offer further ... 
Download PDFPrinter Friendly Version
06/05/15Medtronic and Samsung Partner to Enhance Diabetes Management and Empower Overall Patient Health
BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Samsung Electronics, a world leader in consumer electronics committed to transformative mobile health and wellness solutions, today announced a partnership to improve diabetes management for the millions of people at risk and currently living with the disease. People with diabetes want convenient access to effectively manage their health from anywhere and at any time.  Medtronic and Samsung Electr... 
 Printer Friendly Version
06/05/15Medtronic Receives FDA Clearance of MiniMed® Connect for More Convenient Access to Personal Diabetes Data
People with Diabetes and Their Loved Ones Will Have Smartphone Access to Diabetes Information; Healthcare Teams Have More Convenient Data Access with Daily Uploads BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed® Connect. Designed to provide a mobile connection to critical information for managing diabetes, MiniMed Connect is the first product to enable people with diabetes t... 
Download PDFPrinter Friendly Version
06/05/15Medtronic Expands Access to Diabetes Device Data Through Agreement with Glooko
Medtronic Aims to Provide People with Diabetes, Their Care Teams and Healthcare Providers with Greater Insights to Improve Care BOSTON - June 5, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way. The partnership will incorporate information from Medtronic insulin pumps and continuous glucose... 
Download PDFPrinter Friendly Version
06/04/15Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference
DUBLIN - June 4, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 36th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 10, 2015, in Rancho Palos Verdes, CA. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 8:00 a.m. PDT (10:00 a.m. CDT). A live audio session of the presentation will be available on June 10, 2015, by clicking on th... 
Download PDFPrinter Friendly Version
06/02/15Medtronic Reports Fourth Quarter and Fiscal Year 2015 Financial Results
Q4 Worldwide Revenue of $7.3 Billion Grew 7% on a Comparable, Constant Currency Basis; 60% as Reported Q4 Non-GAAP Diluted EPS of $1.16; GAAP EPS were Break-even Q4 U.S. Revenue of $4.1 Billion Grew 8% on a Comparable Basis; 67% as Reported FY15 Revenue of $20.3 Billion Grew 19% as Reported, or 6% on a Comparable, Constant Currency Basis Q4 Free Cash Flow of $1.7 Billion; GAAP Cash Flow from Operations of $1.9 Billion Company Sets Initial FY16 Revenue Growth Outlook and EPS Guidance ... 
Download PDFPrinter Friendly Version
05/21/15Medtronic CEO Omar Ishrak to Speak at Sanford Bernstein Strategic Decisions Conference
DUBLIN - May 21, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Sanford Bernstein 31st Annual Strategic Decisions Conference on Friday, May 29, 2015, in New York. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 11:00 a.m. EDT (10:00 a.m. CDT). A live audio webcast of the presentation will be available on May 29, 2015, by clicking on the Investors ... 
Download PDFPrinter Friendly Version
05/20/15Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial Disease Shows Strong Results in Long Lesions
First Report of Findings from IN.PACT Global Study's Imaging Cohort Presented at EuroPCR PARIS -- May 20, 2015 -- Presented for the first time today at EuroPCR during the "Hot line" session on "Peripheral interventions," new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic plc (NYSE: MDT) successfully treated long lesions in the superficial femoral and popliteal arteries. Prof. Dierk Scheinert, chairman of the divisio... 
Download PDFPrinter Friendly Version
05/19/15Medtronic Announces Preliminary Fourth Quarter and Fiscal Year 2015 Revenue Results
  Preliminary Q4 Worldwide Revenue of Approximately $7.3 Billion Grew 7% on a Comparable, Constant Currency Basis; 60% as Reported Preliminary Q4 U.S. Revenue of Approximately $4.1 Billion Grew 8% on a Comparable Basis; 67% as Reported Preliminary FY15 GAAP Revenue of Approximately $20.3 Billion Grew 19% as Reported, or 6% on a Comparable, Constant Currency Basis Company Tightens Fourth Quarter Adjusted EPS Expectations DUBLIN - May 19, 2015 - Medtronic plc (NYSE: MDT) today ann... 
Download PDFPrinter Friendly Version
05/18/15New resources help healthcare providers understand, diagnose mystery strokes
DALLAS - May 18, 2015 - A new guide helps healthcare professionals better understand and diagnose strokes of unknown cause. The free resource is part of an American Heart Association/American Stroke Association initiative in collaboration with Medtronic plc (NYSE: MDT) which aims to reduce the rate of recurrent strokes in the U.S. Every year, nearly 800,000 Americans have a stroke, the fifth leading cause of death and a primary cause of disability. The most common type of stroke, called "... 
Download PDFPrinter Friendly Version
05/18/15Data Show Medtronic Quadripolar CRT Technology Optimizes Treatment for Heart Failure Patients
Positive Results from Two Studies Featured at Heart Rhythm Society 36th Annual Scientific Sessions DUBLIN and BOSTON - MAY 18, 2015 -Medtronic plc (NYSE: MDT) today announced study results demonstrating that its quadripolar cardiac resynchronization therapy (CRT) system gives physicians more options to optimize CRT delivery, which may improve heart failure patients' response to the therapy. During Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston, data fro... 
Download PDFPrinter Friendly Version
05/15/15Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months
Long-term Citadel/Centurion Clinical Trial Findings and Independent Data Presented at Heart Rhythm Society 36th Annual Scientific Sessions DUBLIN and BOSTON - MAY 15, 2015 - Medtronic plc (NYSE: MDT) today announced that its TYRX(TM) Antibacterial Envelope reduces major cardiac device site infections by 80 percent, up to 12 months after implantation. These data were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston. The Citadel/Centurion Clini... 
Download PDFPrinter Friendly Version
05/15/15Global Clinical Trial Finds Medtronic Micra® Transcatheter Pacemaker Meets Initial Safety and Performance Measures
Initial Safety and Performance Data of World's Smallest Pacemaker Featured in Late-Breaking Session at Heart Rhythm 2015 DUBLIN and BOSTON - May 15, 2015 - Medtronic plc (NYSE: MDT) today announced study results of its Micra® Transcatheter Pacing System (TPS), which demonstrated that the miniaturized pacemaker has met its initial safety and performance measures. In the largest report to date of a transcatheter pacing system, 100 percent of the first 140 patients who received the Micra TPS exper... 
Download PDFPrinter Friendly Version
05/14/15Global Trial Finds Medtronic Micra® Transcatheter Pacemaker Meets Initial Safety Measures in Wide Range of Patients
Initial Safety Data on World's Smallest Pacemaker Presented at Heart Rhythm 2015 DUBLIN and BOSTON - May 14, 2015 - Medtronic plc (NYSE: MDT) revealed today the first safety data on its Micra® Transcatheter Pacing System (TPS). In the largest reported sample of a transcatheter pacing system to date, the first 140 patients in the Medtronic Micra TPS Global Clinical Trial showed 100 percent were successfully  implanted with the Micra TPS. The data were presented at Heart Rhythm 2015, the Heart Rh... 
Download PDFPrinter Friendly Version
05/14/15Medtronic Evera MRI ICD Clinical Study Meets Safety and Efficacy Endpoints
Late-Breaking Session at Heart Rhythm 2015 Features World's First Randomized Study of an MRI-Conditional Implantable Cardioverter Defibrillator Undergoing Full-Body MRI Scans; Study Simultaneously Published in JACC DUBLIN and BOSTON - May 14, 2015 - Medtronic plc (NYSE: MDT) today announced clinical trial results for the Medtronic Evera MRI(TM) SureScan® implantable cardioverter defibrillator (ICD) following MRI scans. The study showed that full-body magnetic resonance imaging (MRI) scans do no... 
Download PDFPrinter Friendly Version
05/14/15Medtronic Responds to Nepal Earthquake
More than $1 Million Given in Financial Aid, Product Donations, Employee Contributions DUBLIN - May 14, 2015 - Medtronic plc (NYSE: MDT) announced today that it has pledged $100,000 to the American Red Cross to support earthquake relief efforts in Nepal, bringing the company's total current response to more than $1 million in cash and products.  The $100,000 directed to the American Red Cross will help it support the Nepal Red Cross in recovery efforts and provide basic needs for injured and ... 
Download PDFPrinter Friendly Version
05/12/15Medtronic Reiterates Announcement Timing of Its Fourth Quarter and Fiscal Year 2015 Financial Results
Preliminary Revenue Results to be Issued on May 19 Financial Results to be Issued and Webcast to be Held on June 2  DUBLIN - May 12, 2015 - Medtronic plc (NYSE: MDT) reiterated today that on Tuesday, May 19, 2015, it will announce preliminary financial results for the fourth quarter and fiscal year 2015, which ended April 24, 2015.  A news release will be issued on May 19, 2015, at approximately 7:30 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com.  The new... 
Download PDFPrinter Friendly Version
05/12/15Medtronic Receives FDA Approval and CE Mark for Arctic Front Advance® ST Cryoballoon to Treat Atrial Fibrillation
Third-Generation Cryoballoon Designed to Allow Enhanced Positioning and Help Improve Capture of Real-Time Data with Achieve® Mapping Catheter DUBLIN - May 12, 2015 - Medtronic plc (NYSE: MDT) today announced the Arctic Front Advance® ST Cryoablation Catheter has received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation. In Europe, where the Cryoballoon has a broader indication, Arctic Front... 
Download PDFPrinter Friendly Version
05/07/15Medtronic Initiates Study of 'In-Office' Insertion of Reveal LINQ(TM) Cardiac Monitor
RIO 2 Study Evaluates Safety and Effectiveness of Moving the Insertion Procedure from Hospital to Office Setting DUBLIN - May 7, 2015 - Medtronic plc (NYSE: MDT) today announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal LINQ In-Office 2 (RIO 2) Study. The world's smallest cardiac monitor was successfully implanted in an office setting at Scripps Clinic in La Jolla, California, by cardiologist John Rogers, M.D. The RIO 2 study will determine... 
Download PDFPrinter Friendly Version
05/06/15Medtronic to Unveil First-of-Its-Kind Clinical Data for Cardiac Therapies at Heart Rhythm 2015
Late-Breaking Clinical Trial Sessions Feature First Data on Evera MRI® ICD and Micra® TPS DUBLIN - May 6, 2015 - Medtronic plc (NYSE: MDT) today announced its schedule of notable clinical studies that will be presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston, including two late-breaking clinical trials featuring the Evera MRI® SureScan® implantable cardioverter-defibrillator (ICD) System and Micra® Transcatheter Pacing System (TPS). Results ... 
Download PDFPrinter Friendly Version
05/05/15Medtronic Announces FDA Clearance and U.S. Launch of the Euphora(TM) Semicompliant Coronary Balloon
Company to Launch "Cath Lab Connect" Informational Portal and Community Website for Cath Lab Professionals DUBLIN - May 5, 2015 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter, a pre-dilatation therapy used during a stent implantation to reopen a narrowed coronary artery caused by plaque buildup.  The first patient case with the Euphora Semicompliant Ba... 
Download PDFPrinter Friendly Version
05/04/15Medtronic Announces Launch of DIVERGENCE(TM) Stand Alone Interbody Cage
DUBLIN - May 4, 2015 - Medtronic plc (NYSE: MDT), today announced the launch of the DIVERGENCE(TM) Stand Alone Interbody Cage. This device is now commercially available for the treatment of anterior cervical interbody fusion procedures in skeletally mature patients with cervical disc disease at one level from the C2-C3 disc to the C7-T1 disc. The announcement was made during the 83rd annual meeting of the American Association of Neurological Surgeons (AANS) in Washington, DC. The DIVERGENCE(TM)... 
Download PDFPrinter Friendly Version
05/04/15Medtronic Receives FDA Clearance for ZEVO(TM) Anterior Cervical Plate System
DUBLIN - May 4, 2015 -Medtronic plc (NYSE: MDT) announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the ZEVO(TM) Anterior Cervical Plate System. This system is now commercially available for the treatment of cervical degenerative disc disease, trauma, tumors, deformity, pseudoarthrosis, and/or failed previous fusions. The ZEVO System represents Medtronic's latest technology for anterior cervical discectomy with fusion (ACDF) procedures. It featu... 
Download PDFPrinter Friendly Version
05/04/15Medtronic Neurosurgery Receives Expanded Indications for the StealthStation® Electromagnetic Surgical Navigation Technology
Catheter and Electrode Placement Now FDA-cleared for Adult and Pediatric Patient Procedures DUBLIN - May 4, 2015 - Medtronic plc (NYSE: MDT) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded indications of specific StealthStation® electromagnetic (EM) surgical navigation system instruments for pediatric and adult cranial and ENT procedures. The clearance for these StealthStation electromagnetic instruments enables additional neurosurgi... 
Download PDFPrinter Friendly Version
04/30/15Medtronic Initiates Study Evaluating Potential of Combination of Pulmonary Vein Isolation and Renal Denervation for Atrial Fibrillation
Enrollment Underway in the U.S. for Groundbreaking Study Involving Three Medtronic Devices: Arctic Front Advance(TM) Cryoballoon, Symplicity Spyral(TM) & Reveal LINQ(TM) ICM DUBLIN - April 30, 2015 - Medtronic plc (NYSE: MDT) today announced the start of a clinical study using Medtronic technologies to determine whether paroxysmal and persistent  atrial fibrillation (AF) can be treated with a combination of two ablation procedures targeting different anatomical locations - specifically, the pul... 
Download PDFPrinter Friendly Version
04/29/15Endurant AAA Stent Graft System from Medtronic Delivers Consistently Strong Results in Abdominal Aortic Aneurysms with Short and Standard 'Neck' Lengths
Analysis of ENGAGE Registry Patients Presented at Charing Cross International Symposium LONDON -- April 29, 2015 -- For endovascular repair of abdominal aortic aneurysms, the Endurant(TM) AAA stent graft system from Medtronic plc (NYSE: MDT) delivered consistently strong results in patients with short and standard neck lengths who were enrolled in the global ENGAGE registry -- the largest contemporary database on the performance of a single company's stent grafts in real-world clinical practice... 
Download PDFPrinter Friendly Version
04/27/15Medtronic Announces Consent Decree with FDA for the Synchromed Drug Infusion System and the Neuromodulation Quality System
Agreement Provides a Path to Resolution with Continued Patient Access DUBLIN - April 27, 2015 - Medtronic plc (NYSE: MDT) announced today that it has reached agreement on the terms of a consent decree with the U.S. Food and Drug Administration (FDA) specific to the company's SynchroMed® drug infusion system and the Neuromodulation quality system. The agreement is subject to approval by the U.S. District Court for the District of Minnesota. Medtronic will be contacting physicians to ensure they ... 
 Printer Friendly Version
04/27/15Medtronic Starts Clinical Study of Endurant Evo AAA Stent Graft System for Endovascular Treatment of Abdominal Aortic Aneurysms
Principal Investigators Perform First Implant of Investigational Medical Device Designed to Expand Applicability of Minimally Invasive Alternative to Open Surgical Repair DUBLIN -- April 27, 2015 -- Medtronic plc (NYSE: MDT) recently began a clinical study to evaluate the safety and effectiveness of the Endurant Evo AAA stent graft system, an investigational medical device designed to expand the applicability of a minimally invasive alternative to open surgical repair for the treatment of abdom... 
Download PDFPrinter Friendly Version
04/22/15Medtronic Announces European Approval of the First and Only Full-Body MR Conditional Deep Brain Stimulation Systems
Updated Labelling Allows Greater Patient Access to MRI DUBLIN - April 22, 2015 - Medtronic plc (NYSE: MDT) today announced that systems within its Activa® portfolio of Deep Brain Stimulation (DBS) Therapy neurostimulators have received European regulatory approval for MR Conditional full-body Magnetic Resonance Imaging (MRI).[*] The expanded approval for full-body MRI scans applies to all patients receiving a new system and to an estimated 13,000 people in Europe already receiving Medtronic DBS... 
Download PDFPrinter Friendly Version
04/21/15Medtronic Begins Enrollment in Feasibility Study of Valiant 'Mona LSA' Branch Thoracic Stent Graft System
Investigational Device Enables Endovascular Repair of Aortic Aneurysms Encroaching on Left Subclavian Artery DUBLIN -- April 21, 2015 -- Medtronic plc (NYSE: MDT) today announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery (LSA). Cleveland Clinic cardio... 
Download PDFPrinter Friendly Version
04/17/15Global Trials Show Addition of Medtronic's Solitaire Device Stent Thrombectomy Procedure in Treatment of Acute Ischemic Stroke Improves Neurological Outcomes
SWIFT PRIME and REVASCAT Confirm Findings of EXTEND-IA, ESCAPE and MR CLEAN, Support Addition of Solitaire Stent Thrombectomy to Current Standard of Care DUBLIN - April 17, 2015 - Two global trials published online in The New England Journal of Medicine (NEJM) and presented at the European Stroke Organisation Conference found that the addition of the Solitaire(TM) device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering strok... 
 Printer Friendly Version
04/14/15Medtronic to Develop Stent Graft System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms Under Exclusive Patent License Agreement with Sanford Health
Collaboration Aims to Expand Treatment Options and Improve Outcomes for Patients DUBLIN, Ireland and SIOUX FALLS, S.D. -- April 14, 2015 -- The global leader in medical technology for endovascular aortic repair (EVAR), Medtronic plc (NYSE: MDT) today announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health. A concept for the novel system, which wa... 
Download PDFPrinter Friendly Version
04/14/15Medtronic Announces CE Mark of World's Smallest Pacemaker, Micra Transcatheter Pacing System
Miniaturized Device Less Than One-tenth the Size of a Conventional Pacemaker and Placed Directly in the Heart DUBLIN - April 14, 2015 - Medtronic plc (NYSE: MDT)today announced it has received CE (Conformité Européenne) Mark of the Micra® Transcatheter Pacing System (TPS), the world's smallest pacemaker. At less than one-tenth the size of traditional pacemakers, the Micra device provides the most advanced pacing technology available while being cosmetically invisible and small enough to be deli... 
Download PDFPrinter Friendly Version
04/13/15IBM and Medtronic to Partner to Improve Diabetes Care
ARMONK, NY and DUBLIN - April 13, 2015 - IBM (NYSE: IBM) and Medtronic (NYSE: MDT) today announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit. With diabetes device data continuously gathered an... 
Download PDFPrinter Friendly Version
04/09/15Medtronic Initiates U.S. Launch of HawkOne(tm) Directional Atherectomy System for Treatment of Peripheral Arterial Disease
Third-Generation System Treats All Plaque Morphologies Including Severe Calcium, While Streamlining Procedural Efficiency DUBLIN -- April 9, 2015 -- Medtronic plc (NYSE: MDT) enhances its leading directional atherectomy portfolio with the U.S. launch of the HawkOne(TM) directional atherectomy system. The HawkOne system provides physicians with a solution to treat all plaque morphologies in patients with peripheral arterial disease, including patients who have plaque blockages that have become se... 
Download PDFPrinter Friendly Version
04/07/15GOLD AF Registry to Capture Real-World Insights Using Medtronic Phased RF Ablation to Treat Patients with Atrial Fibrillation
DUBLIN - April 7, 2015 - Medtronic plc (NYSE: MDT) today announced the first patient enrollment in the GOLD AF Registry, a first-of-its-kind, prospective, observational clinical study of its Phased Radiofrequency (RF) Ablation technology for treating patients with symptomatic atrial fibrillation (AF). The multicenter registry will provide real-world insights into the procedural use and treatment outcomes of the Pulmonary Vein Ablation Catheter® (PVAC) GOLD, multi-electrode ablation catheter and ... 
Download PDFPrinter Friendly Version
04/02/15Medtronic Acquires Diabeter, Innovative Diabetes Care Provider
DUBLIN - April 2, 2015 - Medtronic plc (NYSE:MDT) today announced its acquisition of Diabeter, an innovative, independent Netherlands-based diabetes clinic and research center dedicated to providing comprehensive and individualized care for children and young adults with diabetes. Together, Medtronic and Diabeter will further develop and expand Diabeter's model of care so more people with diabetes can enjoy greater freedom and better health. This acquisition combines the strengths of Medtronic a... 
Download PDFPrinter Friendly Version
04/01/15EverFlex(TM) Peripheral Stent from Medtronic Delivers Sustained Patency in Long, Complex Lesions
Three-Year Data from DURABILITY II Study Published inCatheterization and Cardiovascular Intervention Journal DUBLIN -- April 1, 2015 ­­-- The EverFlex(TM) self-expanding peripheral stent system from Medtronic plc (NYSE: MDT) has proven to provide sustained patency in the treatment of long, complex lesions in the superficial femoral (SFA) and popliteal arteries, according to the three-year results of the DURABILITY II study, which are reported in the recent issue of Catheterization and Cardiova... 
Download PDFPrinter Friendly Version
04/01/15Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation
DUBLIN - April 1, 2015 - Medtronic plc (NYSE:MDT) today announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a unique, phased clinical program studying renal denervation in uncontrolled hypertension. This announcement follows investigational device exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). The program will begin with two global studies designed to address the confounding factors encountered in the SYMPLICITY HTN-3 clinical trial, including medi... 
Download PDFPrinter Friendly Version
03/31/15Medtronic CoreValve® System Receives FDA Approval for Transcatheter Valve-In-Valve Procedures
 First TAVR Device Indicated for Replacement of Failed Surgical Heart Valves Expands Patient Population That Can Benefit from Minimally Invasive Procedure DUBLIN - March 31, 2015 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the CoreValve® System for valve-in-valve (VIV) procedures in patients whose surgical aortic heart valves have failed. The CoreValve System is the first transcatheter heart valve approved in the U.S. for VIV procedu... 
Download PDFPrinter Friendly Version
03/30/15Medtronic Announces Japanese Regulatory Approval of CoreValve® System
DUBLIN - March 30, 2015 - Medtronic plc (NYSE: MDT) today announced Japanese regulatory approval for the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis (AS) unable to undergo surgery, and for whom treatment with the CoreValve is determined to be the best option. Japanese regulatory authorities granted approval of the CoreValve system for transcatheter aortic valve implantation (TAVI) based on robust data from the CoreValve U.S. Pivotal Trials and the Medt... 
Download PDFPrinter Friendly Version
03/26/15Medtronic Completes Acquisition of Sophono, Inc., Minimally Invasive Bone Conduction Hearing Implant Technology
Acquisition Expands Medtronic's ENT Portfolio with Innovative Hearing Restoration Therapy DUBLIN - March 26, 2015 - Medtronic plc (NYSE: MDT) announced today that it has completed the acquisition of Sophono, Inc., a privately held developer and manufacturer of innovative magnetic hearing implants in Boulder, Colorado. This acquisition enables Medtronic's Ear Nose and Throat (ENT) business to continue its focus on novel therapies and innovative technology solutions and supports Medtronic's thera... 
 Printer Friendly Version
03/25/15Medtronic Highlights New Data in JAMA Surgery Demonstrating Significant Cost Savings and Reduced Patient Hospital Stays Following Minimally Invasive Surgery
Study Shows Patients Who Underwent Laparoscopic Colon Resections Left Hospital Faster, Required Significantly Less Follow Up Care and Fewer Medicines Than Patients Who Underwent Open Surgery DUBLIN - March 25, 2015 - Adding to the clinical benefits and improved patient outcomes associated with minimally-invasive surgery (MIS), Medtronic plc (NYSE: MDT) today highlighted new data demonstrating that patients who underwent minimally invasive colon resection procedures were able to leave the hospit... 
Download PDFPrinter Friendly Version
03/18/15Protégé GPS Self-Expanding Peripheral Stent System Receives FDA Approval for Use in Treating Iliac Artery Stenosis
DUBLIN -- March 18, 2015 -- Medtronic plc (NYSE: MDT) today announced that its Protégé(TM) GPS(TM) self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries.  The news follows the nine-month results of the DURABILITY Iliac study, which were presented at the 2014 VIVA conference in Las Vegas. The results demonstrated the safety and effectiveness of the Protégé GPS ... 
Download PDFPrinter Friendly Version
03/16/15Medtronic Seeks Runners with Medical Technology for 2015 "Global Heroes" Team
APPLICATIONS NOW OPEN:  Selected Runners Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October DUBLIN - March 16, 2015 - Medtronic announced today that applications are open to runners around the world who benefit from medical technology to represent their country on the tenth Medtronic Global Heroes team.  All runners with eligible medical devices are welcome to apply, regardless of device manufacturer. In nine years, 209 runners representing 28 dif... 
Download PDFPrinter Friendly Version
03/15/15Medtronic CoreValve® System Sustains Superior Survival Benefit Over Open Heart Surgery at Two Years
Investigators Conclude that Results Presented as ACC.15 Late-Breaking Clinical Trial Suggest that Self-Expanding TAVR Should be Considered New Standard of Care DUBLIN and SAN DIEGO - March 15, 2015 - Medtronic plc (NYSE: MDT) today unveiled new, highly anticipated two-year data from the High Risk Study of the CoreValve U.S. Pivotal Trial, which continued to show superior survival benefit at two years for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to patient... 
Download PDFPrinter Friendly Version
03/14/15Medtronic to Initiate Clinical Study of Drug-Filled Stent Following Successful Preclinical Results
Novel Platform Enables Controlled, Polymer-Free Drug Elution, Designed to Help Address Next-Generation Technology Challenges  DUBLIN and SAN DIEGO - March 14, 2015 - Advancing its interventional coronary portfolio with breakthrough engineering concepts in device design and technology, Medtronic plc (NYSE: MDT) unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed contro... 
Download PDFPrinter Friendly Version
03/14/15Medtronic CoreValve® Evolut(TM) R System Yields Exceptional Outcomes in First Clinical Study
No Mortality or Stroke at 30-days and Excellent Procedural Results with Next-Generation Recapturable Valve  DUBLIN and SAN DIEGO - March 14, 2015 - Medtronic plc (NYSE: MDT) today announced initial clinical outcomes for its next-generation CoreValve® Evolut(TM) R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population.  Data from the Evolut R Study, which enrolled 60 patients from six center... 
Download PDFPrinter Friendly Version
03/12/15Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting Stent in United States
Next-Generation Device with CoreWire Technology to be Studied in Wide Spectrum of Patients, Including the Smallest Coronary Arteries  DUBLIN - March 12, 2015 - Medtronic plc (NYSE: MDT) today announced the start of its Resolute Onyx(TM) Clinical Program in the United States, which will evaluate the Resolute Onyx(TM) drug-eluting stent (DES) in patients who have coronary artery disease.  Included in the first phase of the study are patients with small vessels that would require a 2.0 mm stent, wh... 
 Printer Friendly Version
03/03/15Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference
DUBLIN - Mar 3, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference in Miami. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic on Wednesday, March 11, 2015, beginning at 9:30a.m. EDT (8:30a.m. CDT). A live audio webcast of the presentation will be available on March 11, 2015, by clicking on the Investors link on t... 
Download PDFPrinter Friendly Version
02/27/15Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference
DUBLIN - Feb 27, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 35th Annual Healthcare Conference in Boston. Michael J. Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a presentation about Medtronic on Tuesday, March 3, 2015, beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be available on March 3, 2015, b... 
Download PDFPrinter Friendly Version
02/27/15Medtronic Announces Irish High Court Approval of Share Premium Reduction
DUBLIN - February 27, 2015 -Medtronic plc (NYSE:MDT) today announced that the Irish High Court has approved the company's share premium reduction petition, creating the distributable reserves needed to support share repurchases or redemptions and payment of the cash dividend of $0.305 per ordinary share that was previously announced on February 13, 2015. The dividend remains payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend re... 
Download PDFPrinter Friendly Version
02/24/15FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux
VenaSeal Closure System, a Next-Generation Chronic Venous Insufficiency Procedure with Demonstrated Safety and Effectiveness DUBLIN - Feb. 24, 2015 ­­- Medtronic plc today announced U.S. Food and Drug Administration approval for VenaSeal(TM) closure system, a minimally invasive procedure that uses a specially formulated medical adhesive to close lower superficial extremities such as the great saphenous vein in patients with symptomatic venous reflux. Venous reflux disease, also known as chro... 
Download PDFPrinter Friendly Version
02/23/15Medtronic Acquires Advanced Uro-Solutions
NURO Percutaneous Tibial Nerve Stimulation System to Enhance Neuromodulation Product Offerings for Treatment of Bladder Control Issues DUBLIN - Feb. 23, 2015 - Medtronic plc (NYSE: MDT) today announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed. Advanced Uro-Solutions develop... 
Download PDFPrinter Friendly Version
02/19/15Study Shows Medtronic Deep Brain Stimulation Therapy for Treatment-Resistant Epilepsy Demonstrates Significant and Sustained Seizure Reduction at Five Years
Results Also Show Sustained Safety, Intervals of Seizure Freedom, Improvements in Quality of Life and Reduction in Seizure Severity DUBLIN - February 19, 2015 - Medtronic plc (NYSE: MDT) today announced five-year results from the pivotal SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, the largest clinical study of deep brain stimulation (DBS) therapy for epilepsy in adults with treatment-resistant (refractory) epilepsy characterized by partial-onset seizures. The ... 
Download PDFPrinter Friendly Version
02/19/15Medicare Approves Transitional Pass-Through Payment for Outpatient Use of Medtronic Drug-Coated Balloon
CMS Decision Provides Supplemental Reimbursement to U.S. Hospitals for New Medical Device with Potential to Improve Standard of Care for Peripheral Arterial Disease in Upper Leg DUBLIN - Feb. 19, 2015 - Medtronic plc (NYSE: MDT) announced today that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for the company's IN.PACT Admiral drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system (OPPS), removing... 
Download PDFPrinter Friendly Version
02/18/15Medtronic Leads Progress Toward an Artificial Pancreas for People with Diabetes
New Data on Future Medtronic Systems and Available MiniMed 640G System Accelerate Progress PARIS - February 18, 2015 - Medtronic plc (NYSE:MDT) is advancing the development and commercialization of artificial pancreas technology with new research demonstrating progress toward future innovations and new systems coming to market. The first clinical study results on Medtronic's Hybrid Closed Loop system will be presented at the upcoming Advanced Technologies and Treatments for Diabetes (ATTD) 8th... 
Download PDFPrinter Friendly Version
02/17/15Medtronic Reports Third Quarter Earnings
Revenue of $4.3 Billion Grew 8% at Constant Currency, 4% as Reported Non-GAAP Diluted EPS of $1.01 Grew 11%; GAAP Diluted EPS of $0.98 Grew 31% U.S. Revenue Grew 8% on Strength of New Products Free Cash Flow of $1.7 Billion; GAAP Cash Flow from Operations of $1.8 Billion Company Completes Acquisition of Covidien at Beginning of Fourth Quarter; Integration Activities Underway DUBLIN - Feb. 17, 2015 - Medtronic plc (NYSE: MDT) today announced financial results for Medtronic, Inc.'s third... 
Download PDFPrinter Friendly Version
02/16/15Medtronic Receives Expanded Indications of the VERTEX® Reconstruction System
Now FDA Cleared for Lateral Mass and Pedicle Screw Fixation in the Posterior Cervical Spine DUBLIN - Feb. 16, 2015 - Medtronic plc (NYSE: MDT), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded  indications of the VERTEX® Reconstruction System.  The new clearance for the VERTEX® family of products allows for lateral mass and pedicle screws to be used as a form of fixation to treat various pathologies occurring in the posterior cervical ... 
Download PDFPrinter Friendly Version
02/16/15Medtronic Announces CE Mark and European Launch of the Euphora(TM) Semicompliant Coronary Balloon Catheter
Semicompliant Balloon Brings Greater Deliverability to Combat Challenging Coronary Lesions DUBLIN - February 16, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter in countries that recognize the CE (Conformité Européene) mark. The first patient case with the Euphora Semicompliant Balloon Catheter was recently performed by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom. It ... 
Download PDFPrinter Friendly Version
02/13/15The American Heart Association - American Stroke Association and Medtronic Collaborate to Reduce Recurrent Strokes
A Leading Cause of Disability and Death, Many Strokes Have No Known Cause DUBLIN and NASHVILLE, TENN. - Feb. 13, 2015 - The American Heart Association/American Stroke Association (AHA/ASA) and Medtronic plc (NYSE: MDT), today announced a collaboration to reduce the rate of recurrent strokes in the U.S. The two organizations will work together over several years to educate, raise awareness and support effective management of patients who have strokes, one of the most devastating diseases affecti... 
Download PDFPrinter Friendly Version
02/13/15Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2015
DUBLIN - February 13, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a cash dividend of $0.305 per ordinary share, conditioned on receipt of Irish Court administrative approval expected to be received by early March 2015. The dividend is payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend represents a 9% increase over the prior year. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, ha... 
Download PDFPrinter Friendly Version
02/12/15FDA Classifies Previous Covidien Field Action for Its Trellis-6(TM) and Trellis-8(TM) Peripheral Infusion Systems As a Class 1 Recall
DUBLIN - February 12, 2015 - Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6(TM) and Trellis-8(TM) peripheral infusion systems has now been classified as a Class 1 Recall by the U.S. Food and Drug Administration. Customers were previously notified by Covidien of the recall on December 15, 2014.  The company has not received any reports of patient injuries related to this issue. If a patient has received treat... 
Download PDFPrinter Friendly Version
02/12/15Study Analyzes Real-World Use of Medtronic's MiniMed 530G System
Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia DUBLIN - February 12, 2015 - Medtronic plc (NYSE:MDT) today announced results of a retrospective analysis based on real-world data from over 20,000 MiniMed® 530G users, which found that the pump's Threshold Suspend feature reduced hypoglycemia, especially at night, without significantly increasing hyperglycemia. The results, titled "Retrospective Analysis of ... 
Download PDFPrinter Friendly Version
02/11/15Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2015
DUBLIN - Feb 11, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for Medtronic, Inc.'s third quarter of its fiscal year 2015 on Tuesday, February 17, 2015. A news release will be issued at approximately 6:15 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic Inc.'s third fiscal quarter, which ended January 23, 2015. Medtronic will host a webcast at... 
 Printer Friendly Version
02/11/15Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
ESCAPE and EXTEND-IA Show Improved Neurological Outcomes with Addition of Stent Thrombectomy DUBLIN - February 11, 2015 - Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire(TM) Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke. Both the EXtending the Time for Thrombo... 
 Printer Friendly Version
02/11/15Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients in 'Real-World' Study
Findings Reinforce Patient Benefit of Reveal LINQ in Real-World Setting New Data Demonstrate Cost-Effectiveness of Long-Term, Continuous Cardiac Monitoring with Potential to Prevent Recurrent Strokes DUBLIN and NASHVILLE - Feb. 11, 2015 - Medtronic plc (NYSE: MDT), today announced the results of a new "real-world" study of patients who have had a cryptogenic stroke (stroke of unknown cause), in which the Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) detected atrial fibrillation i... 
Download PDFPrinter Friendly Version
02/10/15British Journal of Surgery Publishes Five-Year ClosureFast(TM) Study Results
Results Demonstrate Durability, Effectiveness of Treatment for Chronic Venous Insufficiency DUBLIN - Feb. 10, 2015 - The ClosureFast(TM) endovenous radiofrequency ablation catheter from Medtronic plc (NYSE: MDT) is safe and effective for the treatment of chronic venous insufficiency (CVI) over five years, according to data published in the February 2015 issue of British Journal of Surgery. The five-year results of the ClosureFast Long-Term European Multi-Center Study demonstrate the durabilit... 
Download PDFPrinter Friendly Version
02/05/15Medtronic's Pipeline(TM) Flex Embolization Device Receives FDA Approval
Minimally-Invasive Flow Diversion Device for Unruptured Brain Aneurysms Designed for More Exact and Controlled Placement1 DUBLIN - February 5, 2015 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Pipeline(TM) Flex embolization device.  Available through a limited U.S. launch in the coming weeks, Medtronic's latest-generation flow diversion device represents an... 
Download PDFPrinter Friendly Version
02/04/15Medtronic Starts U.S. Launch of IN.PACT Admiral Drug-Coated Balloon for Treatment of Peripheral Arterial Disease in Upper Leg
First Uses of New Medical Device Following FDA Approval Take Place at Hospitals Nationwide DUBLIN - Feb. 4, 2015 - U.S. hospitals this week began using a new medical device from Medtronic plc (NYSE: MDT) called the IN.PACT Admiral drug-coated balloon (DCB) to treat patients with peripheral arterial disease (PAD) in the upper leg, a common cardiovascular condition that causes leg pain and increases the risk of heart attack and stroke. Recently approved by the U.S. Food and Drug Administration, ... 
Download PDFPrinter Friendly Version
02/03/15FDA Grants Pre-Market Approval for Medtronic Melody® Transcatheter Pulmonary Valve
Previously Approved Under Humanitarian Device Exemption (HDE), Melody Valve Shows Safety and Effectiveness in Patients with Congenital Heart Disease DUBLIN and MINNEAPOLIS - February 3, 2015 - Medtronic plc (NYSE: MDT), today announced that its Melody® Transcatheter Pulmonary Valve (TPV) received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) based on strong clinical evidence from three clinical studies demonstrating the valve's effectiveness in delaying ope... 
Download PDFPrinter Friendly Version
02/03/15Medtronic Initiates Trial Evaluating Cryoballoon for Early Persistent AF
Enrollments Underway in France and Germany DUBLIN and MINNEAPOLIS - Feb. 3, 2015 - Medtronic plc (NYSE: MDT) today announced the initiation of the Cryo4 Persistent AF (Cryoballoon Ablation for Early Persistent Atrial Fibrillation) clinical trial. The trial will evaluate the 12-month clinical outcomes of cryoballoon ablation for isolating the pulmonary veins, without additional ablation strategies, using the Medtronic Arctic Front AdvanceTM Cryoballoon system to treat patients with early persist... 
Download PDFPrinter Friendly Version
02/02/15Cardiocom, Medtronic's Patient Monitoring Services Business, Announces Partnerships with Home Health Care Companies
With New LHC Group Service Agreement, Medtronic Now Serves Four of the Five Largest Home Health Care Companies in the United States DUBLIN and MINNEAPOLIS - Feb. 2, 2015 - Medtronic plc (NYSE: MDT) announced today a partnership agreement between its Cardiocom business and LHC Group (NASDAQ: LHCG), a U.S. provider of home health, hospice and comprehensive post-acute healthcare services, to provide integrated clinical telehealth services and medical technology to their patients.  This agreement ... 
 Printer Friendly Version
02/02/15Medtronic Expands Access to the Next Generation CoreValve Evolut R System with New Valve Sizes
CE Mark Approval Received for New 26 mm and 29 mm Valves MINNEAPOLIS - February 2, 2015 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européene) Mark for the 26 mm and 29 mm sizes of the CoreValve® Evolut(TM) R System, a next generation self-expanding valve that advances performance and deliverability during transcatheter aortic valve implantation (TAVI), while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new pos... 
Download PDFPrinter Friendly Version
01/29/15Studies Show Benefits of Medtronic SmartShock(TM) Technology and Physician Reports in Protecting Patients from Inappropriate Shocks
New Results from PainFree SST, Shock-Less Studies, Involving Nearly 7,000 Patients, Published in HeartRhythm DUBLIN and MINNEAPOLIS - Jan. 29, 2015 - Medtronic plc (NYSE: MDT) today announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm. The data show that treating patients with Medtronic implantable cardiac devices equipped with SmartShockTM Technology, and that providing clinicians with proactive reports, help physicians deliver lifesa... 
Download PDFPrinter Friendly Version
01/28/15Medtronic Study Finds CoreValve® System Benefits Aortic Stenosis Patients with Prior Coronary Bypass Surgery
Analysis is First to Show Significant Advantages for Transcatheter Aortic Valve in Patients with Prior CABG DUBLIN and SAN DIEGO - January 28, 2015 - Medtronic plc (NYSE: MDT) revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve® System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass ... 
Download PDFPrinter Friendly Version
01/26/15Medtronic Completes Acquisition of Covidien
DUBLIN, Ireland - January 26, 2015 - Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, announced today that it has successfully completed the previously announced acquisition of Covidien plc (NYSE: COV). Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc.  Shares of Medtronic plc are expected to begin trading on the New York Stock Exchange (NYSE) under the symbol "MDT" on Tuesday, J... 
Download PDFPrinter Friendly Version
01/26/15Medtronic's Pending Acquisition of Covidien Approved by Irish High Court
Transaction Anticipated to Close on January 26, 2015 MINNEAPOLIS AND DUBLIN, Ireland - January 26, 2015 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Irish High Court has sanctioned the Covidien scheme of arrangement pursuant to which Medtronic will acquire Covidien under a new holding company incorporated in Ireland to be named Medtronic plc.  With the Court's approval of the scheme of arrangement, Medtronic and Covidien anticipate that the transaction, wh... 
Download PDFPrinter Friendly Version
01/23/15Medtronic Introduces Enhanced Therapy to Treat Debilitating Symptoms of Serious Stomach Disorder
FDA-Approved System May Provide Long-Term Symptom Relief for Patients Suffering from Gastroparesis MINNEAPOLIS - January 23, 2015 -Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval, under a humanitarian device exemption* (HDE),for the Medtronic Enterra® II System. The system is used to treat chronic, intractable (drug-refractory) nausea and vomiting associated with gastroparesis of diabetic or unknown origin when more conserva... 
Download PDFPrinter Friendly Version
01/22/15Covidien Reports First-Quarter 2015 Results
First-quarter net sales up 2% (up 6%, excluding foreign exchange rate movement) First-quarter diluted GAAP earnings per share were $1.12; excluding specified items, adjusted diluted earnings per share were $1.11 DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 22, 2015-- Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2015. First-quarter net sales of $2.69 billion increased 2% ... 
Download PDFPrinter Friendly Version
01/21/15Medtronic Launches MiniMed 640G System, Breakthrough in Artificial Pancreas Technology, Outside the U.S.
New SmartGuard(TM) Technology Helps People with Diabetes Manage the Challenges of Hypoglycemia MINNEAPOLIS - January 21, 2015 - Medtronic, Inc. (NYSE:MDT) today announced the start of the global launch of the MiniMed(TM) 640G System, the next breakthrough toward an artificial pancreas.  With the introduction of Medtronic's exclusive SmartGuard(TM) technology, MiniMed 640G is designed to help people with diabetes achieve better glucose control through advanced protection from hypoglycemia. The ... 
Download PDFPrinter Friendly Version
01/16/15Medtronic Awards $150,000 Locally in Health Access Grants
Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved SANTA ANA, CALIF. - Jan. 16, 2015 - The Lestonnac Free Clinic and CHOC Children's Foundation each received a two-year Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare in Orange County.  Each organization was nominated by a team of Medtronic employees working at the Medtronic Orange County site in San... 
Download PDFPrinter Friendly Version
01/12/15Medtronic Highlights Growth Opportunities at J.P. Morgan Healthcare Conference
SAN FRANCISCO -- Jan. 12, 2015 -- Chairman and CEO Omar Ishrak discussed the future of Medtronic, Inc. (NYSE: MDT) during a presentation to investors at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco today.  The presentation outlined the company's continued focus on creating long-term value in healthcare through its three key strategies of therapy innovation, globalization and economic value. The pending acquisition of Covidien was also highlighted, which is expected to close... 
Download PDFPrinter Friendly Version
01/12/15Medtronic Awards $150,000 Locally in Health Access Grants
Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved Goleta, CA - January 12, 2015 - Santa Barbara Neighborhood Clinics, Direct Relief and Jodi House Brain Injury Support Center each received a two-year $50,000 Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare.  Each was nominated by a team of Medtronic Neurosurgery employees working in Goleta, CA. The... 
Download PDFPrinter Friendly Version
01/08/15Medtronic-Sponsored European Clinical Trial to Evaluate Cryoballoon Ablation as First-Line Treatment for Patients with Symptomatic Paroxysmal Atrial Fibrillation
MINNEAPOLIS - Jan. 8, 2015 - Medtronic, Inc., (NYSE:MDT) today announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Arctic Front Advance(TM) cryoballoon as a first-line treatment for atrial fibrillation (AF) patients. While medication is currently considered first-line treatment for AF, clinical research indicates that half of all patients with symptomatic disease do not respond to drug therapy1; earlier ablation may improve tre... 
Download PDFPrinter Friendly Version
01/07/15New Clinical Trial Will Evaluate Antibacterial Envelope in Cardiac Implantable Electronic Device Patients at Risk for Major Infections
Medtronic Announces First Patient Enrollment in the WRAP Infection Clinical Trial MINNEAPOLIS - Jan. 7, 2015 - Medtronic, Inc. (NYSE: MDT)  today announced the first patient enrollment in the WRAP Infection Clinical Trial, which will evaluate the effectiveness of the TYRX(TM) Absorbable Antibacterial Envelope in reducing major infections in patients with cardiac implantable electronic devices (CIEDs) at risk for infection. The global clinical trial also will assess healthcare costs related to t... 
Download PDFPrinter Friendly Version
01/06/15Medtronic Shareholders Approve Proposals Related to Medtronic's Acquisition of Covidien
MINNEAPOLIS - Jan. 6, 2015 - Medtronic, Inc. (NYSE: MDT) announced that all proposals related to Medtronic's acquisition of Covidien were approved by Medtronic's shareholders today.  Based on preliminary vote results, the proposal to adopt the transaction agreement and approve the merger was approved by shareholders owning approximately 95.66 percent of the shares voted at the meeting and approximately 75.18 percent of the outstanding Medtronic shares as of the record date.  The final vote resu... 
Download PDFPrinter Friendly Version
01/06/15Announcement under Irish Takeover Rules -- Results of Covidien plc's Shareholder Meetings
This Announcement is Being Made Solely to Comply with the Requirements of the Irish Takeover Rules. the Information Set out Herein Concerning the Results of Covidien plc's Shareholder Meetings on January 6, 2015 Will Also Be Set out in Covidien plc’s Form 8-K to Be Filed on January 6, 2015 DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 6, 2015-- On January 6, 2015, Covidien plc, a public limited company organized under the laws of Ireland, held a spec... 
 Printer Friendly Version
01/05/15Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
MINNEAPOLIS - Jan 5, 2015 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 33rd annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 12, 2015, by clicking on the Investo... 
Download PDFPrinter Friendly Version
01/05/15Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg
Pivotal Study Shows New Medical Device Provides Exceptional Clinical Outcomes and Reduces Need for Costly Repeat Procedures MINNEAPOLIS -- Jan. 5, 2015 -- Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's IN.PACT Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) in the upper leg, a serious and common cardiovascular condition that causes pain in the legs and is known to be a... 
Download PDFPrinter Friendly Version
X